Synthesis and in vitro muscarinic activities of a series of 3-(pyrazol- 3-yl)-1-azabicyclo[2.2.2]octanes

Bioorganic and Medicinal Chemistry

Volumn 8, Issue 2, 2000, Pages 449-454

  Plate, Ralf ^a   Plaum, Marc J M ^a   Hulst, Rob G A V D ^a   De Boer, Thijs ^a  

^a NV ORGANON   (Netherlands)

Author keywords

3 (pyrazol 3 yl) 1 azabicyclo 2.2.2 octanes; Muscarinic antagonist; Neurotransmitters muscarinic agonist

Indexed keywords

OXOTREMORINE; PIRENZEPINE; QUINUCLIDINE DERIVATIVE;

ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CHOLINERGIC ACTIVITY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; GUINEA PIG; ILEUM; NONHUMAN; RAT;

ANIMALS; BICYCLO COMPOUNDS; BRAIN; CHOLINERGIC AGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; OCTANES; RATS;

ANIMALIA; CAVIA PORCELLUS; SUS SCROFA;

EID: 0033997162     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(99)00299-0     Document Type: Article

References (24)

1. Mash D.C., Flynn D.D., Potter L.T. Science. 228:1985;1115.
2. Araujo D.M., Lapchak P.A., Robitaille Y., Gauthier S., Quirion R. Naunyn-Schmiedeberg's Arch. Pharmacol. 342:1988;625.
3. Eagger S.A., Levy R., Sahakian B.J. Lancet. 337:1991;989.
4. Lamy P.P. C N S Drugs. 1:1994;146.
5. Maltby N., Broe G.A., Creasey H., Jorm A.F., Christensen H., Brooks W.S. Br. Med. J. 308:1994;879.
6. Asthana S., Raffaele K.C., Berardi A., Greig N.H., Haxby J.V., Schapiro M.B., Soncrant T.T. Alzheimer Dis. Assoc. Disord. 9:1995;223.
7. Davis K.L., Hollander E., Davidson M., Davis B.M., Mohs R.C., Hovath T.B. Am. J. Psychiatry. 144:1987;468.
8. Hollander E., Davidson M., Mohs R.C., Horvath T.B., Davis B.M., Zemishlany Z., Davis K.L. Biol. Psychiatry. 22:1987;1067.
9. Soncrant T.T., Raffaele K.C., Asthana S., Beradi A., Morris P.P., Haxby J.V. Psychopharmacology. 112:1993;421.
10. Asthana S., Raffaele K.C., Berardi A., Greig N.H., Morris P.P., Schapiro M.B., Rapoport S.I., Blackman M.R., Soncrant T.T. Psychoneuroendocrinology. 20:1995;623.
11. Anon. Trends in Pharmacological Sciences. Receptor & Ion Channel Nomenclature Supplement, 1997. p 4.
12. Levey A.I. Life Sci. 52:1993;441.
13. Flynn D.D., Ferrari-DiLeo G., Levey A.I., Mash D.C. Life Sci. 56:1995;869.
14. Freedman S.B., Dawson G.R., Iversen L.L., Baker R., Hargreaves R.J. Life Sci. 52:1993;489.
15. Fawson G.R., Bayley P., Channell S., Iversen S.D. Psychopharmacology. 113:1994;361.
16. Sedman A.J., Bockbrader H., Schwarz R.D. Life Sci. 56:1995;877.
17. Plate R., Plaum J.M., Boer Th. de, Andrews J.S, Rae D.R., Gibson S. Bioorg. Med. Chem. 4:1996;227.
18. Plate R., Plaum J.M., Boer Th. de, Andrews J.S. Bioorg. Med. Chem. 4:1996;239.
19. Plate, R. Eur. Patent Application No. 92.202227.2, 1992.
20. Olek B.S., Blaney F.E., Brown F., Clark M.S.G., Hadley M.S., Hatcher J., Riley G.J., Rosenberg H.E., Wadswporth H.J., Wyman P. J. Med. Chem. 34:1994;2726.
21. Freedman S.B., Beer M.S., Harley E.A. Eur. J. Pharmacol. 156:1988;133.
22. Sheridan R.D., Sutor B. Neuroscience Letters. 108:1990;273.
23. For more details see: Plate, R.; Plaum, M. J. M.; Pintar P.; Jans, C.G.; Boer, Th. de; Dijcks, F. A.; Ruigt, G.; Andrews, S. Bioorg. Med. Chem. 1998, 6, 1403.
24. De Graaf J.S., De Vos C.J., Steenbergen H.J. J. Pharmacol. Meth. 10:1983;113.